
Assembly Biosciences (ASMB) Stock Forecast & Price Target
Assembly Biosciences (ASMB) Analyst Ratings
Bulls say
Assembly Biosciences is well-positioned with multiple potential treatments in its pipeline, strong partnerships in place, and a solid financial position. While there are risks involved, the potential for success for these treatments and the potential for milestone payments and partnerships make this stock an attractive opportunity for investors, with a target price of $50 per share.
Bears say
Assembly Biosciences is facing a critical decision in mid-2026 regarding their partnership with Gilead for the development of their long-acting helicase-primase inhibitors (HPI) for recurrent genital herpes, which could potentially replace their traditional milestones and royalties. However, with a relatively small U.S. market for hepatitis delta virus and a risk-adjusted value of $21 per share for their HPI franchise in recurrent genital herpes, a negative outlook is warranted due to the uncertainty and limited market potential for their pipeline products.
This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Assembly Biosciences (ASMB) Analyst Forecast & Price Prediction
Start investing in Assembly Biosciences (ASMB)
Order type
Buy in
Order amount
Est. shares
0 shares